Showing 3551-3560 of 4164 results for "".
- Aldeyra Therapeutics Achieves Statistical Significance for All Endpoints in Phase 3 Trial of Reproxalap in Allergic Conjunctivitishttps://modernod.com/news/aldeyra-therapeutics-achieves-statistical-significance-for-primary-and-secondary-endpoints-in-phase-3-trial-of-reproxalap-in-allergic-conjunctivitis-1/2481676/Aldeyra Therapeutics announced positive topline results from the phase 3 INVIGORATE-2 clinical trial of 0.25% reproxalap ophthalmic solution (reproxalap), an investigational new drug, in patients with allergic conjunctivitis. The clinical trial successfully achieved statistical significance for t
- Atsena Therapeutics Receives FDA Clearance of IND Application for ATSN-201, an Investigational Gene Therapy for the Treatment of X-linked Retinoschisishttps://modernod.com/news/atsena-therapeutics-receives-fda-clearance-of-ind-application-for-atsn-201-an-investigational-gene-therapy-for-the-treatment-of-x-linked-retinoschisis/2481580/Atsena Therapeutics, a clinical-stage gene therapy company, announced the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2 clinical trial of ATSN-201 in patients with X-linked retinoschisis (XLRS). ATSN-201 leverages one of the company&rsquo
- Frontera Therapeutics Doses First Patient in a Trial of FT-002 Gene Therapy for the Treatment of X-Linked Retinitis Pigmentosahttps://modernod.com/news/frontera-therapeutics-doses-first-patient-in-a-trial-of-ft-002-gene-therapy-for-the-treatment-of-x-linked-retinitis-pigmentosa/2481415/Frontera Therapeutics announced that it has dosed the first patient in a clinical trial of its gene therapy product, FT-002, which is being studied for the treatment of X-linked retinitis pigmentosa (XLRP) and is Frontera’s third gene therapy product candidate to enter the clinic.
- EyeCare Partners Expands Footprint in Northern Ohio with Three Additional Practiceshttps://modernod.com/news/eyecare-partners-expands-footprint-in-northern-ohio-with-three-additional-practices/2481171/EyeCare Partners announced that it has expanded its presence in Northern Ohio through a partnership with Novus Clinic, Corrective Eye Center, and Retina Specialists of Ohio (RSO). Additionally, the company plans to build a new Ambulatory Surgery Center (ASC) as well as a 16-exam lane clinic,
- EyeCare Partners Launches New Innovation Centerhttps://modernod.com/news/eyecare-partners-launches-new-innovation-center/2481118/EyeCare Partners (ECP) announced the launch of the EyeCare Partners Innovation Center, which aims to improve the delivery and quality of eye care and advance clinical eye health education. The Innovation Center will be led by ECP’s Chief Clinical Officer, Antonio Capone, Jr., MD.
- Opus Genetics Expands its Leadership Teamhttps://modernod.com/news/opus-genetics-expands-its-leadership-team/2480981/Opus Genetics, a gene therapy company developing treatments for inherited retinal diseases, announced the appointments of Vikram Arora, PhD, DABT, as Vice President of Non-Clinical Development; Erin O’Neil, MD, as Vice President of Clinical Development; and Sarah Tuller, JD, RAC, as Vice Pr
- Nanodropper Announces Growth in Partnerships and Availabilityhttps://modernod.com/news/nanodropper-announces-increases-in-partnerships-and-availability/2480921/Nanodropper, a volume-reducing adaptor for eye drop bottles, announced major growth over the last 12 months, including an 832% increase in clinic partnerships, expanding to more than 840 clinic locations since June of 2021. Nanodropper has also more than doubled its team as it finalized rese
- Brim Biotechnology and Ora Announce Partnership to Accelerate Development of Regenerative Peptide Therapy, BRM421, for Dry Eyehttps://modernod.com/news/brim-biotechnology-and-ora-inc-announce-new-partnership-to-accelerate-development-of-regenerative-peptide-therapy-brm421-for-dry-eye-syndrome/2480867/Brim Biotechnology announces it has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate, BRM421, for dry eye syndrome (DES). Brim intends to initiate phase 3 clinical studies with Ora’s support later this year.
- RetinAI Receives FDA Clearance for Discovery Image Management Platform for Ophthalmologyhttps://modernod.com/news/retinai-receives-fda-clearance-for-discovery-image-management-platform-for-ophthalmology/2480826/RetinAI Medical AG announced it has received FDA 510(k) clearance for RetinAI Discovery, the company’s image and data management platform for interoperability across the clinical and clinical study ecosystems in ophthalmology. The Discovery platform can be
- CORE Names “Top 10 of 2021” Scientific Papers for Eye Care Communityhttps://modernod.com/news/core-names-top-10-of-2021-scientific-papers-for-eye-care-community/2480525/In a year like no other, the Centre for Ocular Research & Education (CORE) has published a record 66 scientific and clinical educational papers on topics that advance academic and clinical knowledge in optometry and ophthalmology. The organization today announced its “Top 10 o